Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Bioceros B.V. announces change of ownership


Utrecht, The Netherlands, February 17th, 2011 - Bioceros B.V. announces that it has successfully realized a change of ownership. This is the result of the purchase of the outstanding shares owned by Forbion, Thuja Capital and Biogeneration Ventures by existing shareholders and the management team.

Bioceros’ CEO, Dr. Bram Bout comments: “The financial round of 2008, which was led by Thuja Capital and Biogeneration Ventures, has allowed us to build a strong, independent service business and to lay the foundation for a product pipeline. We are therefore pleased and proud that we can offer our investors this exit. Bioceros will further grow its service business by expanding its technology platform and spin out its early-stage products in a separate legal entity.”

Dr. Mark de Boer (chairman) and Dr. Oscar Schoots, MBA, will remain members of the Supervisory Board of Bioceros.

About Bioceros.

Bioceros is a biotech company focusing on pre-clinical development of protein products, with an emphasis on monoclonal antibodies. Bioceros’ technology platform covers early pre-clinical development of monoclonal antibodies, including generation of monoclonal antibodies in mice, making high protein producing CHO and PER.C6® cell lines, assay development and pre-clinical manufacturing at 20L scale. This is all Quality Controlled, using state of the art serum-free culture media, such that the generated cell lines can be used for GMP manufacturing. Bioceros is preferred vendor of DSM Biologics and Crucell for PER.C6® cell line generation services.
Bioceros uses this technology platform to offer services to the industry and academia, and to develop its own pipeline of monoclonal antibody products.

Bioceros is located in Utrecht, the Netherlands. For more information, please visit www.bioceros.com or contact:


Remco M. Brandt
COO
Bioceros BV
Yalelaan 46
3584 CM UTRECHT
The Netherlands

Phone: +31(0) 30-253 7910
Cell: +31(0) 6-1012 7709
Fax: +31(0) 30-253 2288
URL: www.bioceros.com


Publisher Contact Information:

Bioceros
+31(0) 30-253 7910
-

Company profile of Bioceros (acquired by Epirus)
Past press releases of Bioceros (acquired by Epirus).

Data


21,120
Tech investments
From our Online Data Service
13,644
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 15€1.2ME-Commerce
Feb 4€0.5MMedical devices
Feb 2€78.0MBiopharmaceuticals
Feb 2€7.2MInternet commerce
Feb 2€31.5MInternet services
Feb 1€0.6MInternet services
Jan 29€4.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Feb 2
Spotcap
online lending platform spotcap raises eur 31.5m in funding

Feb 2
Mission Therapeutics
mission therapeutics raises £60 million to progress development of ...

Feb 2
Watchmaster
watchmaster snags $8 mln series b

Jan 21
Endeit Capital
endeit capital holds €125 million final close for new fund

Jan 20
ysura GmbH
ysura lands top talent joern jackowski and enters otc market





About usContact usLegal Information
Copyright © 1999-2016
Emerging Technology Research Europe Inc. All rights reserved.